CG Oncology (CGON) return on equity (ROE)

Return on equity · fiscal 2025
-21.4%

CG Oncology (CGON) earned a return on equity of -21.4% in fiscal 2025 (the year ended December 31, 2025). That is 9.4 percentage points lower than the -12.0% of fiscal 2024. Figures as of 17 Nov 2026, 22:25 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-21.4%
Change on fiscal 2024
−9.4 pts
Highest on record
-12.0%fiscal 2024
Lowest on record
-28.3%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

CG Oncology return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was -12.0% in fiscal 2024 and the lowest -28.3% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is -26.3%.

History · 4 fiscal years

Return on equity by fiscal year

CG Oncology return on equity (ROE), year by year

CG Oncology (CGON) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-21.4% 9.4 pts down
2024-12.0% 14.3 pts up
2023-26.3% 2.0 pts up
2022-28.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of CG Oncology and comparable companies
CompanyReturn on equityFiscal year
Oruka Therapeutics ORKA-22.3%2025
Arrowhead Pharmaceuticals ARWR-1439.4%2026
MSA Safety MSA20.4%2025
CG Oncology CGON-21.4%2025
Kodiak Sciences KOD-146.1%2025
Lantheus Holdings LNTH21.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CGON

CG Oncology, figure by figure

CG Oncology (CGON) overview: price, valuation and scorecardAll health care companies by market value

CG Oncology return on equity (ROE): questions and answers

What is CG Oncology's return on equity?

CG Oncology (CGON) earned a return on equity of -21.4% in fiscal 2025 (the year ended December 31, 2025). That is 9.4 percentage points lower than the -12.0% of fiscal 2024.

Is CG Oncology's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is -26.3%.

What are the highest and lowest return on equity figures on record for CG Oncology?

Across the 4 fiscal years on record (2022–2025), the highest was -12.0% in fiscal 2024 and the lowest -28.3% in fiscal 2022.

How is CG Oncology's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CG Oncology (CGON) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/CGON/roe

Underlying data: Yahoo Finance.